A 12-Year Study of Slotted Palladium-103 Plaque Radiation Therapy for Choroidal Melanoma: Near, Touching, or Surrounding the Optic Nerve

Maheshwari, Abhilasha; Finger, Paul T.

doi:10.1016/j.ajo.2018.01.025

Cited by 18 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a large series of 650 juxtapapillary choroidal melanomas treated with various plaques (iodine, palladium, ruthenium, and iridium) and adjuvant TTT, recurrence rates of 14% and 21% at 5 and 10 years, respectively, were reported [7]. In addition, plaques with a slot for accommodating the optic nerve have been reported to have 98.1% tumour control [11]. We have not seen similar results with notched ruthenium plaques.…”

Section: Discussionmentioning

confidence: 59%

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

et al. 2021

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the outcomes of juxtapapillary choroidal melanomas treated with notched ruthenium-106 plaques. Methods: Juxtapapillary choroidal melanomas (tumours within 2 disc diameters from the optic disc) treated with notched ruthenium-106 plaques (Eckert & Ziegler, BEBIG, Berlin, Germany) at the Scottish Ocular Oncology Service between 2009 and 2015 were retrospectively reviewed. The data were analysed with respect to various outcome measures including recurrence, complications, vision, and eye preservation. Results: We reviewed 40 patients with a median tumour diameter of 8.4 mm (range 5–17 mm) and a median thickness of 2.5 mm (range 1.1–6 mm). AJCC tumour category distribution was 62.5% T1, 32.5% T2, and 5% T3 tumours. The mean presenting vision was 0.3 logMAR, and the mean final vision was 0.7 logMAR, with 62.5% retaining >1.0 logMAR and 50% retaining >0.3 logMAR at the final follow-up. The median follow-up was 51 months (14–100 months). Over the maximum follow-up time, 13 tumours (32.5%) recurred. Six of these were treated with salvage proton beam therapy (PBT), 2 with transpupillary thermotherapy followed by PBT, and 5 with enucleation. The final eye retention rate was 87.5%. Complications included maculopathy (10%), retinal detachment (5%), neovascular glaucoma (2.5%), and diplopia (2.5%). The observed risk of recurrence over 5 years was 31% (95% CI: 14.1%, 47.8%), and the risk of enucleation over 5 years was 11.5% (95% CI: 0.9%, 21.8%). Conclusion: Juxtapapillary choroidal melanomas treated with notched ruthenium plaques have a high recurrence rate and frequently need salvage treatment with PBT for tumour control. This has led to a change in our practice toward offering PBT as the first-line treatment for these patients.

show abstract

Section: Discussionmentioning

confidence: 59%

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…12 Additional radiation effects on the eye include cataract formation, radiation optic neuropathy, retinal detachment, neovascular glaucoma, nerve-fiber layer infarcts, retinal hemorrhages, and vitreous hemorrhage. 11,[13][14][15] Radiation damage can be detected and classified through clinical examination, fluorescein angiography, indocyanine green angiography, or optical coherence tomography (OCT). [16][17][18] High-resolution OCT classification (either swept source or spectral domain) is now the standard in detecting and monitoring radiation-induced macular edema, and it can be graded on a 1 to 5 scale.…”

Section: Introductionmentioning

confidence: 99%

“…Additional radiation effects on the eye include cataract formation, radiation optic neuropathy, retinal detachment, neovascular glaucoma, nerve-fiber layer infarcts, retinal hemorrhages, and vitreous hemorrhage. 11,13 -15…”

Section: Introductionmentioning

confidence: 99%

Aflibercept for Radiation Maculopathy (ARM Study): Year-2 Extension of a Prospective Clinical Study

Murray

Latiff²,

Villegas

et al. 2020

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Purpose: This work describes the 2-year results of the Aflibercept for Radiation Maculopathy (ARM) randomized clinical study that evaluated intravitreal vascular endothelial growth factor antagonist therapy in radiation maculopathy delivering aflibercept using a second-year collapsed, every-6-weeks, treat-and-adjust interval. Methods: Forty patients were enrolled in an institutional review board–approved clinical trial and randomly assigned to aflibercept treatment via 1 of 2 regimens: fixed, every-6-week treatment or variable, treat-and-adjust therapy centered around 6 weeks. All patients had a diagnosis of treated uveal melanoma with documented tumor control, and they had visually compromising radiation maculopathy. At conclusion of year 1, the first 30 patients were offered a collapsed single-arm variable of an every-6-weeks treat-and-adjust aflibercept injection schedule for an additional treatment year. Results: Baseline best-corrected visual acuity (BCVA) was 20/63 at ARM study entry 20/62 at the institution of the year-2 extension. At ARM study entry baseline, spectral domain–optical coherence tomography mean central retinal thickness was 432 µm and was 294 µm at the same institution. At the 2-year study’s conclusion, 76.7% (23 of 30) of eyes were better than 20/50, and only 6.7% (2 of 30) ended with a BCVA below 20/200. Final mean BCVA was 20/62 and final mean spectral domain–optical coherence tomography central retinal thickness was 286 µm, but as in year 1, this reduction in number of injections was not statistically significant. Conclusions: Aflibercept is effective in treating radiation maculopathy with maintained visual acuity at 2 years but continues to require an ongoing treatment approach to stabilize radiation maculopathy.

show abstract

“…At present, according to the demands of patients, their own vision and general conditions, the treatment mainly includes transpupillary thermotherapy and local resection. Most patients with choroidal melanoma are already at the advanced stage at the time of treatment, and platinum-based chemotherapy is the majority of patients with advanced choroidal melanoma [4]. Cisplatin (DDP) is the most common platinum-based rst-line chemotherapy drug [5].…”

Section: Introductionmentioning

confidence: 99%

circBIRC6 regulates cisplatin resistance of choroidal melanoma via positively modulating ERK by sponging miR-503-3p

Nie

Jin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background/AimscircRNA plays a key regulatory role in various human tumors. This study was carried out to investigate the molecular mechanism of circBIRC6 in the regulation of choroidal melanoma cisplatin (DDP) resistance. MethodsThe expression of circBIRC6 in choroidal melanoma tissues and cells (MUM-2B, MUM-2B / DDP) was detected by RT-qPCR. The function of circBIRC6 in DDP resistance of choroidal melanoma was analyzed by functional loss and overexpression experiments. DDP inhibition rate was detected by MTT method. Western blot was used to analysis the protein levels of P-gp, MRP1 and ERK. The relationship between circBIRC6, miR-503-3p and ERK was analyzed by CircRIP and luciferase reporter vector assay.ResultcircBIRC6 was up-regulated in choroidal melanoma, and it was significantly raised in choroidal melanoma tissues and cells that are resistant to DDP. CircBIRC6 regulated DDP resistance of choroidal melanoma cells by binding to miR-503-3p. ERK was directly targeted by miR-503-3p, and ERK inhibited miR-503-3p-induced DDP resistance. Finally, the expression of circBIRC6 was positively correlated with ERK, and it was verified that circBIRC6 regulated ERK by targeting miR-503-3p.ConclusionCircBIRC6 regulated the expression of ERK choroidal melanoma cells and DDP resistance via miR-503-3p. These results suggested that the knockout of circBIRC6 may provide an effective treatment strategy for choroidal melanoma.

show abstract

A 12-Year Study of Slotted Palladium-103 Plaque Radiation Therapy for Choroidal Melanoma: Near, Touching, or Surrounding the Optic Nerve

Cited by 18 publications

References 39 publications

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

Aflibercept for Radiation Maculopathy (ARM Study): Year-2 Extension of a Prospective Clinical Study

circBIRC6 regulates cisplatin resistance of choroidal melanoma via positively modulating ERK by sponging miR-503-3p

Contact Info

Product

Resources

About